Induction of apoptosis in glioblastoma cells by inhibition of protein kinase C and its association with the rapid accumulation of p53 and induction of the insulin-like growth factor-1-binding protein-3

Biochemical Pharmacology

Volumn 55, Issue 10, 1998, Pages 1711-1719

  Shen, Li ^a   Glazer, Robert I ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; IGFBP3; p53; PKC

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; DNA FRAGMENT; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COLONY FORMATION; CONTROLLED STUDY; DNA CLEAVAGE; DRUG EFFECT; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BRAIN NEOPLASMS; CELL NUCLEUS; DNA FRAGMENTATION; ENZYME INHIBITORS; FLOW CYTOMETRY; GENES, CDC; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; PROTEIN KINASE C; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032524977     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00045-8     Document Type: Article

References (60)

1. Kikkawa U, Kishimoto A, Nishizuka Y. The protein kinase C family Heterogeneity and its implications . Annu Rev Biochem. 58:1989;31-44.
2. Blobe G, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 13:1994;411-431.
3. Gescher A. Towards selective pharmacological modulation of protein kinase C-Opportunities for the development of novel antineoplastic agents. Br J Cancer. 66:1992;10-19.
4. Glazer R. Protein kinase C in multidrug resistance, neoplastic transformation and differentiation. Kuo J. Protein Kinase C. 1994;171-198 Oxford University Press, Oxford.
5. Couldwell WT, Uhm JH, Antel JP, Yong VW. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery. 29:1991;880-887.
6. Couldwell WT, Antel JP, Yong VW. Protein kinase C activity correlates with the growth rate of malignant gliomas Part II. Effects of glioma mitogens and modulators of protein kinase C . Neurosurgery. 31:1992;717-724.
7. Yong VW, Kim SU, Pleasure DE. Growth factors for fetal and adult human astrocytes in culture. Brain Res. 444:1988;59-66.
8. Xiao H, Goldthwait DA, Mapstone T. The identification of four protein kinase C isoforms in human glioblastoma cell lines PKC α, γ, ε, and ζ J Neurosurg. 81:1994;734-740.
9. Misra-Press A, Fields AP, Samols D, Goldthwait DA. Protein kinase C isoforms in human glioblastoma cells. Glia. 6:1992;188-197.
10. Vertosick F. The role of protein kinase C in the growth of human gliomas Implications for therapy . Cancer J. 5:1992;328-331.
11. Couldwell WT, Weiss MH, Weiner LP, Degiogio CM, Hinton DR, Ehresmann GR, Conti PS, Apuzzo MJ. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high dose tamoxifen. Neurosurgery. 32:1993;485-490.
12. Baltuch GH, Couldwell WT, Villemure JG, Yong VW. Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery. 33:1993;495-501.
13. Ahmad S, Mineta T, Martuza RL, Glazer RI. Antisense expression of protein kinase Cα inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery. 35:1994;904-909.
14. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol Pharmacol. 50:1996;236-242.
15. Vaux DL, Strasser G, Langleben A, Villemure IG. The molecular biology of apoptosis. Proc Natl Acad Sci USA. 93:1996;2239-2244.
16. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
17. Reed JC, Miyashita T, Takayama S, Wang H-G, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hamada M. Bcl-2 family protein Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy . J Cell Biochem. 60:1996;23-32.
18. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
19. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
20. Fisher D. Apoptosis in cancer therapy Crossing the threshold . Cell. 78:1994;539-542.
21. Haimovitz-Friedman A, Balaban N, McLoughlin M, Ehleiter D, Michaeli J, Vlodavsky I, Fuks Z. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res. 54:1994;2591-2597.
22. Batistatou A, Green LA. Internucleosomal DNA cleavage and neuronal cell survival/death. J Cell Biol. 122:1993;523-532.
23. Motyka B, Griebel PJ, Reynolds JD. Agents that activate protein kinase C rescue sheep ileal Peyer's patch B cells from apoptosis. Eur J Immunol. 23:1993;1314-1321.
24. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, Loganzo F Jr, Kelsen DP, Fuks Z, Albino AP. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J Natl Cancer Inst. 87:1995;1394-1399.
25. Couldwell WT, Hinton DR, He A, Chen TC, Sebat I, Weiss MH, Law RE. Protein kinase C inhibitors induce apoptosis in human malignant cell lines. FEBS Lett. 345:1994;43-46.
26. Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J-I. Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. J Neurosurg. 83:1995;1008-1016.
27. Behrens M, Martinez JL, Mortatilla C, Renart J. Apoptosis induced by protein kinase C inhibition in a neuroblastoma cell line. Cell Growth Differ. 6:1995;1375-1380.
28. Ahmad S, Glazer RI. Expression of the antisense cDNA to protein kinase C-α attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol. 43:1993;858-862.
29. Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W, Kalden JR. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res. 22:1994;5506-5507.
30. Borellini F, Glazer RI. Induction of Spl-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem. 268:1993;7923-7928.
31. Telford WG, King LE, Fraker PJ. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degeneration by flow cytometry. Cytometry. 13:1992;137-143.
32. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 55:1995;735-738.
33. Zhan Q, Carrier F, Fornance AJ Jr. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol. 13:1993;4242-4250.
34. Matsumoto H, Shimura M, Omatsu T, Okaichi K, Majima H, Ohnishi T. p53 proteins accumulated by heat stress associate with heat shock proteins HSP72/HSC73 in human glioblastoma cells. Cancer Lett. 87:1994;39-46.
35. Godbout R, Miyakoshi J, Dobler KD, Andison R, Matsuo K, Allalunis-Turner MJ, Takebe H, Day RS II. Lack of expression of tumor-suppressor genes in human malignant glioma cell lines. Oncogene. 7:1992;1879-1884.
36. Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun. 237:1997;690-693.
37. Rajah R, Valentine B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 172:1997;12181-12188.
38. Davis PD, Elliott LH, Harris W, Hill CH, Hurst SA, Keech E, Kumar MKH, Lawton G, Nixon JS, Wilkinson SE. Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J Med Chem. 35:1992;994-1001.
39. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marmé D, Schächtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem. 268:1993;9194-9197.
40. 2/M phase transition of cell cycle. J Biol Chem. 171:1996;15045-15053.
41. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, Yung WKA. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst. 89:1997;1036-1044.
42. deVente JE, Kukoly CA, Bryant WO, Posekany KJ, Chen J, Fletcher DJ, Parker PJ, Pettit GJ, Lozano G, Cook PP, Ways DK. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. J Clin Invest. 96:1995;1874-1886.
43. Nigro JM, Baker SJ, Presinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:1989;705-708.
44. Louis DN, von Deimling A, Chung RY, Rubio M-P, Whaley M, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol. 52:1993;31-38.
45. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA, Ewen ME. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 386:1997;177-181.
46. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marmé D, Rapp UR. Protein kinase Cα activates RAF-1 by direct phosphorylation. Nature. 364:1993;249-252.
47. Carroll MP, May WS. Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells. J Biol Chem. 269:1994;1249-1256.
48. Sozeri O, Vollmer K, Liyanage M, Frith D, Kour G, Mark GE, Stabel S. Activation of the c-Raf protein kinase by protein kinase C phosphorylation. Oncogene. 7:1992;2259-2262.
49. Mittnacht S, Weinberg RA. G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell. 65:1991;381-393.
50. Templeton DJ. Nuclear binding of purified retinoblastoma gene product is determined by cell cycle-regulated phosphorylation. Mol Cell Biol. 12:1992;435-443.
51. Galaktionov K, Jessus C, Beach D. Rafl interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev. 19:1995;1046-1058.
52. Miyashita T, Reed JC. bcl-2 Gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:1992;5407-5411.
53. Chresta CM, Masters JRW, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 56:1996;1834-1841.
54. Thomas A, Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance . Oncogene. 12:1996;1055-1062.
55. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54:1994;3131-3135.
56. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
57. Rinaudo MS, Su K, Falk LA, Haldar S, Mufson RA. Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood. 86:1995;80-88.
58. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol. 16:1996;4952-4960.
59. Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol. 16:1996;4961-4971.
60. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9:1995;2170-2183.